Ratiometric methods of analysis have been developed for the selective determination of lactate or citrate in microlitre samples of human serum, urine or prostate fluids following comparison of anion binding affinities for a family of nine luminescent europium(III) complexes.
Lactate and citrate are essential oxy-anions in nature. Their determination is typically based on multi-component enzymatic methods of analysis, using lactic acid dehydrogenase (LDH) or citrate lyase, 1 most commonly linked to absorption spectrophotometric analysis of NAD + at 340 nm. The limit of sensitivity of the spectrophotometric assay is about 0.1 mM; and therefore requires a relatively high sample volume. The assay sensitivity can be improved to~1 mM by employing fluorimetric detection of NADH. However, in each case, sample pre-treatment and deproteination are required to eliminate interfering sample components.
Lactate and citrate are key metabolites in the intermediary metabolism of the cell; lactate is the important end product of anaerobic and hypoxic glucose metabolism via glycolysis. It is also the major product of aerobic glycolysis that characterizes the metabolism of tumour cells. Lactate analysis of serum is important in sports medicine and in clinical and experimental medicine; for example, lactate is elevated in liver damage and liver disease. Citrate is the key metabolite in the Krebs cycle (citric acid cycle) of virtually every aerobic cell. The synthesis and oxidation of citrate provides the major energy supply (~70%) of cells. Citrate is also the source of acetyl CoA that is required for fatty acid and cholesterol synthesis which is essential for proliferating cells, tissue regeneration, embryogenesis and steroid hormone synthesis. Determination of citrate levels is important in clinical conditions and in normal cell metabolism. Diminished citrate levels in urine have been linked to various aspects of kidney dysfunction, for example in the pathogenesis of nephrolithiasis and nephrocalcinosis. atively non-invasive screening/diagnostic procedure for prostate cancer.
3b Citrate concentrations in malignant prostate tissue decrease from the normal tissue value of~10 000-12 000 nmols/gram to~1000-3000 nmols/gram. Concentrations in prostatic fluid samples thus decrease from the normal range of~50-200 mM in healthy males to cancer levels of~2-20 mM. These normal and clinical relationships illustrate the need to develop simple, fast and chemoselective methods to determine the concentration of these oxy-anions in biological fluids, such as cell extracts, serum, urine and particularly in prostate or seminal fluid samples (seminal fluid is normally composed of 50% prostate fluid thereby defining the citrate level).
To address this issue, we report direct, non-enzymatic methods for measurement of lactate and citrate in microlitre samples of biological fluids, using single component emissive europium(III) complexes. We have been developing sensitive luminescence methods of analysis based on the reversible binding of anions to an emissive metal centre. Examples of reversible anion binding in water to single-component, well-defined metal complexes are of considerable current interest.
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Of particular note is the chelation of lactate and citrate to lanthanide(III) centres, involving cooperative ligation of the hydroxyl and a-carboxylate groups-verified by luminescence, X-ray and NMR studies.
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This process involves reversible displacement of lanthanide bound water molecules. The associated change in lanthanide coordination environment is signalled by modulation of the lifetime and spectral form of the europium luminescence. The sensitivity of the electric dipole allowed DJ = 2 (around 616 nm) and DJ = 4 (700 nm) europium emission bands to changes in the Eu coordination environment is well known.
The affinity of the anion for the Eu(III) centre is determined by Coulombic attraction (lactate: pK a 3.86; citrate: 3.13, 4.76 and 6.40, 298 K, I = 0) and by the steric demand at the metal created by the other coordinated ligands. With this background in mind, and based on our appreciation of selective anion binding at Ln(III) centres in complexes of macrocyclic heptadentate ligands, 6,9 we have examined the anion binding behaviour of a series of Eu(III) complexes, [EuL n ], (n = 1-9), varying complex charge and ligand steric demand in order to modulate affinity for lactate and citrate. The desired affinity constant and working range of the measurement is determined by the nature and ionic composition of the background medium, typically made up of potentially interfering anions, protein (e.g. albumin 0.7 mM) and certain cations, (e.g. Ca 2+ , 1.2 mM; Zn 2+ , 10 mM, Mg 2+ , 0.9 mM) that can perturb the equilibrium speciation.
Each of the complexes examined † is based on a common macrocyclic core and includes a heterocyclic azaxanthone (l exc 337 nm) or azathiaxanthone (l exc 380 nm) moiety in which the pyridyl nitrogen is bound to Eu, facilitating the sensitisation of lanthanide emission. 10 In addition, in the cationic complexes 0.1 HEPES, 0.1 M NaCl, 0.9 mM NaH 2 PO 4 , 30 mM NaHCO 3 and 2.3 mM sodium lactate) in the absence and presence of 2 mM MCl 2 (M = Ca, Zn and Mg) revealed an apparent affinity constant that increased by about two log units.
Pronounced citrate/lactate selectivity was observed with the positively charged complexes, e.g. for [Eu.L 3 ] + , the ratio of affinity constants is 42:1. Lactate binding is preferred with the more sterically demanding mono-anionic complexes. For [Eu.L 9 ] -, the lactate/citrate ratio was 30/1. These complexes were selected for further study, analysing for citrate or lactate respectively in human serum, urine, saliva, seminal and prostate fluid samples using the luminescence method, and comparing the data obtained to measurements made using enzyme kits.
14 For lactate and citrate analyses using the Eu emission method, a calibration curve must be determined in an appropriate background medium, allowing the working range of the measurement to be defined. Thus, in a 'simulated prostate fluid' background containing 0.3 mM HSA, 0.1 M NaCl, 4 mM KCl, 3 mM NaHCO 3 , 4 mM CaCl 2 , 2 mM ZnCl 2 , 5 mM MgCl 2 (pH 6.5, 0.1 M HEPES), Fig. 1 , modulation of Eu emission (10 mM concentration) is evident over the lactate concentration range zero to 1 mM. Typically, a 5 mL sample of fluid, (seminal or prostate) was diluted into pH 6.5 buffer by a factor of 10, and the solution analysed in a 50 mL optical cuvette (l exc 336 nm). The intensity ratio of the 692/619 or 613/622 or 613/619 nm emission bands in [Eu.L 9 ] -was measured and the lactate concentration deduced by reference to the calibration curve. Samples of lactate in urine (3.5 mM), seminal fluid (3.8 mM) prostate fluid (4 mM) and reconstituted human serum (1.9 mM) were found to be within 10% of the concentration deduced enzymatically. † In saliva, which contains high levels of lactic acid dehydrogenase, each method gave a zero reading for lactate (± 0.2 mM).
Similar procedures may be used to analyse the citrate content of clinical biofluids using [Eu.L 3 ] + . In this case, typically a 1 mL sample of prostatic fluid is diluted ¥200. To obviate any interference due to variations in lactate concentration in male prostate fluid samples, calibration measurements were made (l exc 365 nm, 10 ms gate time, 50 mL optical cell) in 'simulated prostate fluid' solution, that contained a large excess of lactate (0.1 M) Fig. 1 .
Citrate was determined in seventeen samples of prostate fluid from healthy male human volunteers, and values ranging from 12 mM to 160 mM were measured. These were confirmed (±10%) by independent analysis (Fig. 2) using a commercially available citrate lyase enzyme kit, for which the amount of bio-fluid required was 25 times greater. Using similar methods, but with a 100-fold dilution of sample, citrate was also determined in the urine of healthy volunteers (range 3.5 to 5.5 mM (±10%)). In summary, rapid luminescence measurements have been developed that allow the determination of citrate or lactate in low volume (<5 mL) samples of various biological fluids. In the citrate analyses using [Eu.L 3 ] + , sample dilution is followed by a time-gated measurement eliminating any interference from concomitant chromophore fluorescence. In particular, this method has been applied to the analysis of citrate in 17 clinical prostate fluid samples, and values varying by an order of magnitude were determined. These studies allow the correlation of measured citrate levels with the health status of the patient. In certain cases, this may be used to confirm or indicate the onset or progression of prostate adenocarcinoma. The optical methods that have been developed are rapid (<5 min) and offer advantages over alternative enzymatic assays that take longer to carry out, require larger sample volumes and need additional sample preparation steps.
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